Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
about
Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemiaABL tyrosine kinases: evolution of function, regulation, and specificityAllosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaFarnesyl transferase inhibitor resistance probed by target mutagenesisEGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly headTwo different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case reportA screen to identify drug resistant variants to target-directed anti-cancer agentsCombining RNA interference and kinase inhibitors against cell signalling components involved in cancer.Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsIn vitro selection of mutant HDM2 resistant to Nutlin inhibitionStructural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaActivation of tyrosine kinases by mutation of the gatekeeper threonineTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Mechanisms of drug resistance in kinases.MEK1 mutations confer resistance to MEK and B-RAF inhibition.BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerActivity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Overcoming mutation-based resistance to antiandrogens with rational drug designSecondary mutations as mediators of resistance to targeted therapy in leukemiaReverse phase protein microarrays advance to use in clinical trialsA Src-like inactive conformation in the abl tyrosine kinase domainAllosteric interactions between the myristate- and ATP-site of the Abl kinaseRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorIdentifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discoveryFluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase FunctionTowards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational DynamicsAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsImatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategyEvolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitorsInterfacial water molecules in SH3 interactions: Getting the full picture on polyproline recognition by protein-protein interaction domains.
P2860
Q21245701-929B8FA9-DED1-4281-A6F2-AE8559F43242Q24299738-9737C132-371E-4E4F-BE89-42F366487D17Q24321968-9BE18E4E-F007-4C86-B420-278AFEA87C28Q24605527-8E319BEB-2B6F-4C6A-80CA-FB343BFDBB41Q24684154-FEF8DC2E-0AE7-4184-A616-C23A8E6B5C02Q24794815-B84D5121-320B-4A26-A11A-3C531B5F8F12Q24800045-2285A249-C00B-4721-905A-4FF5831BE500Q24806543-DCCAE5E8-DF32-4EFB-AAD9-B59E39B460B5Q24814879-C049F956-5C45-4904-8EA3-008E0213F4C8Q27028181-87460381-2147-467D-8306-502A1FF324B7Q27322456-FC96665F-66D3-4242-9F39-917FBED6D25DQ27640723-BA8248F4-18C7-4AC6-9AE8-356CFE0250A9Q27652166-D7501CAF-14D2-4CA2-BE09-EB6678542639Q27658951-7ABCC22D-1F4A-4CD9-8656-5983EF229932Q27667482-C1D47D11-62D3-4030-B944-B668841D734CQ27692567-F1E9A94B-C1E7-4521-8509-9A896030A9D7Q27777362-AC704748-44F4-4FB3-919A-B18A1B4791EEQ27851610-644C9D62-7020-47A8-8B1A-9572843CC696Q27851628-C5ECE63C-4ADA-4F04-A723-7763BFED35EDQ27851672-D4283F21-BD06-47A4-8740-C1519104CB76Q27851681-F8D11F33-D9FD-42BA-8BB3-C67D5E83ECD8Q27851710-4F3A0F51-88BB-4E2C-A62A-EF4DE9CB524EQ27851767-CA48210D-C3F7-4F6B-BDEB-43261E9BF9D5Q27853086-E47EBE1A-45FB-44A8-A98D-95E56BEDEFEAQ27853136-7ACDD4FB-DB1B-4DF7-B190-E662C57A9CF8Q28044590-8B3E1276-B72E-4110-A5EA-5AB49DA7D16EQ28087213-051CDA74-2791-4EB4-A4CE-1FDB4293747AQ28384553-9F56DB87-725D-4BBC-B010-467C99AF5CA1Q28469170-D57F0C6A-897C-48A4-9F9B-D771AB52E789Q28476718-CA2FE394-69FE-4C43-9ADA-0C247D978529Q28482297-9542D609-2BBC-453D-AF66-E05F95D45A67Q28540918-08475E66-85A6-4E34-BC6C-9ACA464AA10CQ28546849-86EFF8DA-C9BC-4054-9231-67D0126E045CQ28551159-92AC603D-AA45-4F26-A598-2D1F1C05DB47Q28586026-E47B6668-FF85-492B-9E41-F007E289C59DQ30008882-01F5935B-70FA-4AB7-92A5-F8B218705B83Q30009238-CE8E04D0-F9B1-428B-8122-0392A339B34BQ30009530-6173EE30-C661-41EA-88FF-EC4238749ED7Q30009947-FA85EF00-C8D5-49C0-A206-65F103564D09Q30010103-FF2E4957-D741-4DDD-8499-FB00A9CFFDC8
P2860
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@en
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@nl
type
label
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@en
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@nl
prefLabel
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@en
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@nl
P1433
P1476
Mechanisms of autoinhibition a ...... led by mutagenesis of BCR-ABL.
@en
P2093
Mohammad Azam
Robert R Latek
P304
P356
10.1016/S0092-8674(03)00190-9
P407
P577
2003-03-01T00:00:00Z